Q1 2021 Results Slides (liminalbiosciences.com) At March 31, 2021: •
Cash & cash equivalents:
CAD 21.6M, Net loss:
CAD $20.5M Admin, selling & marketing expenses (highest): $6.7M, Plasma div: $6.0M, Small molecule $5.5M, Financing $2.4M
Thus, burn is $20M per qtr so their cash is gone by end of June but they received $17M cash for plasma collection centres and $5M for plasma division (another quarter of cash)
Liminal - Product Pipeline (liminalbiosciences.com) - no link to any further Fez/4050 activities
Milestones as noted in Q1 2021 presentation Potential monetization of PRV, if granted by FDA on successful BLA approval - 2021
Fezagepras Phase 1 multiple ascending dose (MAD) study in the United Kingdom in healthy
volunteers Ongoing ------- nothing more said since end of May
Anticipated initiation of a global Phase 2b clinical trial in patients with idiopathic pulmonary fibrosis (IPF) subject to the results of the phase 1 study H1-2022 -------
cancelled with little explanation!!! HUGE drop in price targets to $4.50 Preparatory work for anticipated Phase 1b/2a clinical trial of fezagepras in the US for patients with high triglyceride levels (hypertriglyceridemia) 2022 ------
cancelled!!! Liminal never shared any market potential so it was not included in price targets GPR84 antagonist Initiate a pre-clinical IND enabling program to support a First-in-Human Phase 1 single ascending dose clinical trial of our GPR84 drug candidate in healthy volunteers for safety and tolerability TBC ------
no dates as it needs to finish preclinical trials and then work with FDA to apply for IND application OXER1 antagonist Initiate a pre-clinical IND enabling program to support a First-in-Human Phase 1 single ascending dose clinical trial of our OXER1 drug candidate in healthy volunteers for safety and tolerability TBC ------ no dates as it needs to finish preclinical trials and then work with FDA to apply for IND application